JPMorgan Starts Upstream Bio (UPB) at Overweight

November 5, 2024 3:03 AM EST Send to a Friend
JPMorgan analyst Tessa Romero initiates coverage on Upstream Bio (NASDAQ: UPB) with a Overweight rating and a price target of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login